Brain Iron Deposition Alterations in Type 2 Diabetes Mellitus Patients With Mild Cognitive Impairment Based on Quantitative Susceptibility Mapping

J Diabetes. 2025 Jan;17(1):e70052. doi: 10.1111/1753-0407.70052.

Abstract

Background: Iron is one of the most important elements in brain that may has a direct impact on the stability of central nervous system. The current study devoted to explore the alterations of iron distribution across the whole brain in type 2 diabetes mellitus (T2DM) patients with mild cognitive impairment (MCI).

Methods: The quantitative susceptibility mapping (QSM) technique was used to quantify the intracranial iron content of 74 T2DM patients with MCI and 86 T2DM patients with normal cognition (NC). The group comparison was performed by a voxel-based analysis. Then we evaluated the relationships between cognitive indicators and magnetic susceptibility value (MSV) measured by QSM of the significant brain areas, which were set as the regions of interest (ROIs). In addition, we analyzed the moderation effects of grey matter volume (GMV) of the related brain areas and several metabolic and cerebrovascular factors on the associations between MSV of ROIs and cognitive characteristics.

Results: T2DM patients with MCI exhibited a lower MSV in the right middle temporal gyrus (MTG) compared to NC group. And in the MCI group, there were significantly negative correlations between MSV of the right MTG and several memory indexes. Furthermore, the moderation effects of GMV of the whole brain and the bilateral MTG on the relationship between MSV of the right MTG and scores of list recognition were significant.

Conclusions: T2DM patients with MCI had a temporary decreased iron content in the right MTG, which may partially compensate for cognitive impairment.

Trial registration: The study was registered at Clinicaltrials.gov (NCT02738671).

Keywords: iron deposition; magnetic resonance imaging; mild cognitive impairment; quantitative susceptibility mapping; type 2 diabetes mellitus.

MeSH terms

  • Aged
  • Brain Mapping / methods
  • Brain* / diagnostic imaging
  • Brain* / metabolism
  • Brain* / pathology
  • Cognitive Dysfunction* / metabolism
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / metabolism
  • Female
  • Gray Matter / diagnostic imaging
  • Gray Matter / metabolism
  • Gray Matter / pathology
  • Humans
  • Iron* / analysis
  • Iron* / metabolism
  • Magnetic Resonance Imaging* / methods
  • Male
  • Middle Aged

Substances

  • Iron

Associated data

  • ClinicalTrials.gov/NCT02738671